Joyson Karakunnel
Board Member
Dr. Karakunnel is an experienced medical oncologist and hematologist with more than 20 years of drug development from target discovery to approval in oncology and hematology. In addition to being a Board member for Precision Biologics, he is also a Board Member for Primevax and Abalytics Oncology.
He currently is the Senior Vice President, Head of Research, Oncology at GlaxoSmithKline (GSK) where he oversees target discovery to clinical proof in concept for programs. Prior to this, he served as interim CMO for ITeos Therapeutics, EVP and CMO at Innate Pharma, and SVP and CMO at Tizona therapeutics. He was founding team for Trishula Therapeutics. Prior to this, he held positions with Arcus Biosciences, and AstraZeneca/MedImmune.
Prior to joining the biopharmaceutical industry, he was at the National Cancer Institute (NCI) and team leader for the hematologic group at Walter Reed National Military Medical Center, Associate Professor at the Uniformed Services University of the Health Sciences and a medical reviewer at the U.S. Food and Drug Administration. Dr. Karakunnel completed his oncology and hematology fellowships at the NCI, his medical training at Annamalai University in India and holds a Masters in Pharmacology from the University of Maryland. He holds a MBA from Indiana University Kelley School of Business.
